2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1337

Myocardial Fatty Acid Metabolism and Perfusion Mismatch in Scintigraphy Predicts Worse Prognosis in Clinically Amyopathic Dermatomyositis

Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

9:00AM-11:00AM: Abstract Number: 1612

Myocardial Infarctions Among Ankylosing Spondylitis Patients in a Large US Insurance Database

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1339

Myositis Specific Anti-Histidyl tRNA Synthetase (HisRS) Autoantibodies Display High Reactivity Against Hisrs Conformational Epitopes and Associate with Lung and Joint Involvement

Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

9:00AM-11:00AM: Abstract Number: 1342

Myositis Specific Antibodies Measured Using a Novel Particle Based Multi-Analyte Assay Resemble Myositis Subsets By Principle Component Analysis

Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

9:00AM-11:00AM: Abstract Number: 1085

Natural Gingerols Inhibit Neutrophil Extracellular Trap Release Elicited By Lupus Autoantibodies

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 996

Neutralizing Effect of Anti-Infliximab Antibodies on Infliximab-Stimulated Human Coronary Artery Endothelial Cells

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1456

Neutrophil Activation Is Associated with Disease Activity and Predicts Development of Erosive Disease and Extra Articular Manifestations in Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1003

Neutrophil Response to Ultraviolet Light in Normal and Lupus Conditions

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1795

New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1464

Newer Generation Cyclic Citrullinated Peptide (CCP) 3.1 Assay in the Diagnosis of Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1552

No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1813

Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1160

Non-Elderly Adults Who Have Never Seen a Health-Care Provider for Chronic Joint Symptoms- Updated Results from National Health Interview Survey 2015

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1069

Non-Receptor Protein Tyrosine Phosphatase 14 (PTPN14) Promotes YAP-Dependent Tgfbeta Signaling in RA FLS

Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1767

Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis

Vasculitis – ANCA-Associated Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].